All In Biotech

NDA 217806 · Eli Lilly and CO

Zepbound

Tirzepatide · Subcutaneous · Glucose-dependent Insulinotropic Polypeptide Receptor Agonist; GLP-1 Receptor Agonist

NovelBreakthrough therapyPriority review

Last checked: Nov 20, 2026Latest source record: Aug 26, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Nov 8, 2023

Approved uses

4

Original approval plus efficacy supplements

Registered trials

242

59 Phase 3, 94 recruiting

FAERS reports

84,243

7,972 serious, 225 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISK OF THYROID C-CELL TUMORS In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether ZEPBOUND causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions ( 5.1 ) and Nonclinical Toxicology ( 13.1 )]. ZEPBOUND is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Contraindications ( 4 )] . Counsel patients regarding the potential risk for MTC with the use of ZEPBOUND and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid...

What it is approved for

From the label in effect Aug 28, 2026.

ZEPBOUND ® is indicated in combination with a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity. ZEPBOUND is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. ( 1 ) to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity. ( 1 ) Limitations of Use: Coadministration with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended. ( 1 ) Limitations of Use ZEPBOUND contains tirzepatide. Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.

Mechanism: Tirzepatide is a GIP receptor and GLP-1 receptor agonist. It contains a C20 fatty diacid that enables albumin binding and prolongs the half-life. Tirzepatide selectively binds to and activates both the GIP and GLP-1 receptors, the targets for native GIP and GLP-1. GLP-1 is a physiological regulator of appetite and caloric intake. Nonclinical studies suggest the addition of GIP may further contribute to the regulation of food intake. Both GIP receptors and GLP-1 receptors are found in areas of the brain involved in appetite regulation. Animal studies show that tirzepatide distributes to and...

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 26, 2026 Supplement 41 · Efficacy LetterLabel
  • Dec 20, 2024 Supplement 13 · Efficacy · priority review Breakthrough therapyLabelMedication GuideLetter
  • Oct 18, 2024 Supplement 6 · Efficacy LetterLabel
  • Nov 8, 2023 Original approval · Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated · priority review NovelLabelLetterReview
24 products under this application
  • ZEPBOUND · TIRZEPATIDE 60MG/2.4ML (25MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • ZEPBOUND KWIKPEN · TIRZEPATIDE 60MG/2.4ML (25MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • ZEPBOUND · TIRZEPATIDE 40MG/2.4ML (16.7MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • ZEPBOUND · TIRZEPATIDE 5MG/0.5ML (5MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • ZEPBOUND KWIKPEN · TIRZEPATIDE 40MG/2.4ML (16.7MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • ZEPBOUND · TIRZEPATIDE 20MG/2.4ML (8.33MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • ZEPBOUND (AUTOINJECTOR) · TIRZEPATIDE 15MG/0.5ML (15MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • ZEPBOUND KWIKPEN · TIRZEPATIDE 20MG/2.4ML (8.33MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • ZEPBOUND · TIRZEPATIDE 15MG/0.5ML (15MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • ZEPBOUND (AUTOINJECTOR) · TIRZEPATIDE 10MG/0.5ML (10MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • ZEPBOUND · TIRZEPATIDE 10MG/0.5ML (10MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • ZEPBOUND (AUTOINJECTOR) · TIRZEPATIDE 5MG/0.5ML (5MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • ZEPBOUND KWIKPEN · TIRZEPATIDE 10MG/2.4ML (4.17MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • ZEPBOUND · TIRZEPATIDE 50MG/2.4ML (20.8MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • ZEPBOUND · TIRZEPATIDE 7.5MG/0.5ML (7.5MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • ZEPBOUND KWIKPEN · TIRZEPATIDE 50MG/2.4ML (20.8MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • ZEPBOUND · TIRZEPATIDE 30MG/2.4ML (12.5MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • ZEPBOUND · TIRZEPATIDE 2.5MG/0.5ML (2.5MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • ZEPBOUND KWIKPEN · TIRZEPATIDE 30MG/2.4ML (12.5MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • ZEPBOUND · TIRZEPATIDE 10MG/2.4ML (4.17MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • ZEPBOUND (AUTOINJECTOR) · TIRZEPATIDE 12.5MG/0.5ML (12.5MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • ZEPBOUND · TIRZEPATIDE 12.5MG/0.5ML (12.5MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • ZEPBOUND (AUTOINJECTOR) · TIRZEPATIDE 7.5MG/0.5ML (7.5MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • ZEPBOUND (AUTOINJECTOR) · TIRZEPATIDE 2.5MG/0.5ML (2.5MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Tirzepatide" as an intervention, any sponsor and status, largest first.

All 242 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • incorrect dose administered14,801
  • nausea9,989
  • drug ineffective5,679
  • diarrhoea5,254
  • injection site pain5,171
  • extra dose administered5,050
  • vomiting4,257
  • constipation3,882
  • fatigue3,138
  • accidental underdose2,613
  • injection site erythema2,451
  • weight increased2,430

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20151
20172
20181
20196
20203
202113
202235
2023119
202411,202
202532,100
202640,761

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zepbound (Tirzepatide)

2024 spending

$387K

Beneficiaries

245

353 claims

Per beneficiary

$1,581

$509.13 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$387,343

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 374 on PubMed

Sponsor: Eli Lilly · Also marketed as Zepbound Kwikpen, Zepbound (Autoinjector)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.